China-based high-value medical device firm Mingche Biotechnology (Suzhou) Co., Ltd has reportedly raised “tens of millions” of renminbi in a pre-Series A financing round. This significant capital raise was led by Suzhou Industrial Park Development Zhidao Equity Investment Partnership and Qianrong Capital, with additional contributions from Haida Investment. The funds will be used to advance the company’s core products and technologies in the medical device sector.
Use of Proceeds
The proceeds from this financing round will be directed towards further developing Mingche Biotechnology’s core products, particularly focusing on the minimally invasive glaucoma drainage tube (MIGS). This investment will support the company’s research and development efforts, clinical trials, and market expansion strategies.
Company Background and Technology Platforms
Mingche Biotechnology has 20 years of experience in hydrogel materials, two-photon micro nano 3D printing, microfluidic, and other advanced technology platforms. The company has successfully advanced its core product into the clinical stage, with a focus on the development of minimally invasive glaucoma drainage tubes. These tubes represent a significant innovation in the treatment of glaucoma, offering a less invasive and more effective solution for patients.-Fineline Info & Tech
